# Angiodynamics Inc: Form 10-Q for the period ended Nov 30, 2016

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2017-01-06
- Accepted by EDGAR: Jan 6, 2017, 15:06 ET
- Period: 2016-11-30
- Accession: 0001275187-17-000005
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000127518717000005/ango-113016x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000127518717000005/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-11-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 6 months, 2016-06-01 to 2016-11-30 | $177.1m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2016-09-01 to 2016-11-30 | $44.0m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months, 2016-06-01 to 2016-11-30 | $87.1m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2016-09-01 to 2016-11-30 | $45.0m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2016-06-01 to 2016-11-30 | $90.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2016-09-01 to 2016-11-30 | $5.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2016-06-01 to 2016-11-30 | $12.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2016-09-01 to 2016-11-30 | $15.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2016-06-01 to 2016-11-30 | $19.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-09-01 to 2016-11-30 | $813.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2016-06-01 to 2016-11-30 | $1.5m | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-09-01 to 2016-11-30 | $681.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2016-06-01 to 2016-11-30 | $2.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-09-01 to 2016-11-30 | $13.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2016-06-01 to 2016-11-30 | $15.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-09-01 to 2016-11-30 | $0.37 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2016-06-01 to 2016-11-30 | $0.41 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-09-01 to 2016-11-30 | $0.37 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2016-06-01 to 2016-11-30 | $0.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-09-01 to 2016-11-30 | 37,146,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2016-06-01 to 2016-11-30 | 37,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2016-06-01 to 2016-11-30 | $22.4m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months, 2016-06-01 to 2016-11-30 | $1.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2016-06-01 to 2016-11-30 | $7.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2016-11-30 | $35.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-11-30 | $147.8m | us-gaap:AssetsCurrent |
| Total assets | at 2016-11-30 | $712.2m | us-gaap:Assets |
| Current liabilities | at 2016-11-30 | $50.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-11-30 | $188.8m | us-gaap:Liabilities |
| Long-term debt | at 2016-11-30 | $110.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2016-11-30 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2016-11-30 | $523.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 25,940 characters.

The following information should be read together with the consolidated condensed financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

### Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

### Executive Overview

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Most of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.

Our sales and profitability growth depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. In recent years we have acquired or developed, and launched several new products, including the AngioVac cannula and circuit, the BioFlo family of products, NanoKnife and the Acculis microwave system, which are all currently contributing to our revenue profile. We recognize the importance of, and intend to continue to make investments in, research and development activities and business development opportunities and feel confident that our existing capital structure and free cash flow generation will allow us to properly fund those activities.

We sell our products in the United States through a direct sales force and outside the U.S. through a combination of direct sales and distributor relationships. We expect our international business to grow in both sales and profit through geographic expansion, market penetration, and increasing our direct presence.

During the first quarter of fiscal 2017, Michael C. Greiner was appointed Executive Vice President and Chief Financial Officer of the Company.

The following financial metrics will assist in evaluating the operating performance of our business for the three and six months ended November 30, 2016 compared to the three and six months ended November 30, 2015:

Three months ended November 30, 2016

- Reported revenue decreased by 0.3% to $89.0 million
- Constant currency revenue decreased by 1%
- Operating income increased by $15.0 million to $15.6 million
- Diluted earnings per share increased by $0.38 to $0.37

Six months ended November 30, 2016

- Reported revenue increased by 2% to $177.1 million
- Constant currency revenue increased by 3%
- Operating income increased by $18.4 million to $19.2 million
- Diluted earnings per share increased by $0.44 to $0.41
- Cash flow from operations increased by $8.1 million to $22.4 million

For our second quarter results, revenue growth was primarily driven by growth in the Peripheral Vascular franchise as a result of opportunities created by the Cook Medical recall. Other favorable trends and growth drivers include the solid performance of BioFlo in both Midlines and Dialysis. The increase in operating income was driven by the change in fair value of the contingent consideration, volume growth, continued margin improvements and reductions in operating expenses.

### Management's Use of Non-GAAP Measures

Net sales “on a constant currency basis” is a non-GAAP measure. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors. Constant currency growth rates are calculated by translating the current period's local currency sales by the prior period’s exchange rate.

Constant currency growth rates are not indicative of changes in corresponding cash flows. The limitation of these non-GAAP measures is that they do not reflect results on a standardized reporting basis. Non-GAAP measures are intended to supplement the applicable GAAP disclosures and should not be viewed as replacements of GAAP results.

### New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note P to our consolidated condensed financial statements in this Quarterly Report on Form 10-Q.

### Results of Operations for the Three Months ended November 30, 2016 and November 30, 2015

For the three months ended November 30, 2016, we reported net income of $13.7 million, or $0.37 per diluted share, on net sales of $89.0 million, compared with a net loss of $0.3 million, or $0.01 per share, on net sales of $89.3 million during the same quarter of the prior year.

### Net Sales

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns.

Net sales for the three months ended November 30, 2016 and November 30, 2015:

| Net Sales by Product Category | Three months ended Nov 30, 2016 | Nov 30, 2015 | % Growth | Currency Impact (Pos) Neg | Constant Currency |
| --- | ---: | ---: | ---: | ---: | ---: |
| Peripheral Vascular | $52,895 | $51,055 | 4% |  |  |
| Vascular Access | 23,553 | 25,020 | (6)% |  |  |
| Oncology/Surgery | 11,780 | 12,471 | (6)% |  |  |
| Total Excluding Supply Agreement | 88,228 | 88,546 | —% | —% | —% |
| Supply Agreement | 801 | 738 | 9% | —% | 9% |
| Total | $89,029 | $89,284 | —% | —% | —% |
| Net Sales by Geography |  |  |  |  |  |
| United States | $70,782 | $70,653 | —% | —% | —% |
| International | 17,446 | 17,893 | (2)% | 1% | (1)% |
| Supply Agreement | 801 | 738 | 9% | —% | 9% |
| Total | $89,029 | $89,284 | —% | —% | —% |

For the three months ended November 30, 2016, net sales decreased $0.3 million to $89.0 million compared to the same period in the prior year.

From a product line perspective, Peripheral Vascular sales increased 4% primarily attributable to increased volume in our core business, primarily Angiographic, which is offsetting softness in the remaining Peripheral Vascular business. Vascular Access sales decreased 6% due to softness in PICCs and ports offset by continued strength in our Midlines and Bioflo Dialysis products. Oncology Surgery sales decreased 6% relating to the timing of capital product sales versus the prior year.

From a geographic perspective, U.S. sales remained consistent due primarily to increased volume in Angiographic, Midlines and our NanoKnife product lines offsetting decreasing revenue in other product lines. International sales decreased 1% on a constant-currency basis, primarily attributable to decreased Peripheral Vascular and Oncology sales offset slightly by increased sales in PICCs.

### Gross Profit, Operating expenses, and Other income (expense)

|  | Three months ended Nov 30, 2016 | Nov 30, 2015 | % Change |
| --- | ---: | ---: | ---: |
| Gross profit | $45.0 | $45.9 | (2)% |
| Gross profit % of sales | 50.6% | 51.4% |  |
| Research and development | $5.9 | $6.2 | (5)% |
| % of sales | 6.6% | 6.9% |  |
| Selling and marketing | $19.5 | $21.4 | (9)% |
| % of sales | 21.9% | 23.9% |  |
| General and administrative | $7.8 | $8.1 | (4)% |
| % of sales | 8.7% | 9.1% |  |
| Medical device excise tax | $— | $1.0 | (100)% |
| % of sales | —% | 1.1% |  |

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead. The decrease in gross profit was due to pricing pressures and the cost markup related to our mix of products for a net $0.9 million decrease compared to the three months ended November 30, 2015.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical, regulatory and medical affairs. R&D expenses decreased $0.3 million for the three months ending November 30, 2016 due to lower project spend of $0.9 million related to implementation of a new product development process that is prioritizing project spend. These savings were partially offset by increases in regulatory and registration costs ($0.7 million).

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities. S&M expenses decreased by $1.9 million for the three months ending November 30, 2016 due to sales and marketing roles that have not been filled, as well as lower commissions ($0.7 million), reduced travel costs ($0.6 million), timing of marketing spend ($0.3 million) and samples management ($0.3 million).

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. G&A expenses decreased $0.3 million for the three months ended November 30, 2016 due to improved benefit claim performance versus in the prior year ($0.8 million) and lower depreciation expense ($0.2 million), partially offset by increased stock based compensation expense ($0.7 million).

Medical device excise tax - Medical devices excise tax is assessed on our US product sales subject to exclusions and adjustments during the second quarters of fiscal 2016. The expense decreased for the three months ending November 30, 2016 compared to the prior year due to the suspension of the medical device excise tax as of the end of December 2015.

|  | Three months ended Nov 30, 2016 | Nov 30, 2015 | $ Change |
| --- | ---: | ---: | ---: |
| Amortization of intangibles | $4.3 | $4.5 | $(0.2) |
| Change in fair value of contingent consideration | $(16.0) | $0.3 | $(16.3) |
| Acquisition, restructuring and other items, net | $7.9 | $3.9 | $4.0 |
| Other expense | $(1.2) | $(1.2) | $— |

Amortization of intangibles - Amortization of intangibles decreased from the three months ending November 30, 2016 to November 30, 2015 primarily due to intangibles that became fully amortized.

Change in fair value of contingent consideration - Represents changes in the contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration. The decrease is due to a gain of $13.4 million that was taken on the AngioVac product as a result of decreases in future sales forecasts that eliminated any excess payments and a gain of $3.1 million on the TiLo product as the milestone will not be achieved. This was partially offset by normal amortization.

Acquisition, restructuring and other items, net - Expense for the three months ended November 30, 2016 consists primarily of $0.4 million in severance, $1.8 million in litigation expense, $2.0 million for the write-off of Embomedics due to termination of the agreement and $3.6 million related to the decision to discontinue our investment in the TiLo product, as described above. The three months ended November 30, 2015 included $0.4 million in accelerated depreciation, $1.3 million in litigation expense and other miscellaneous items.

Other expenses - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs. Expenses were consistent year over year in composition.

|  | Three months ended Nov 30, 2016 | Nov 30, 2015 |
| --- | ---: | ---: |
| Income tax expense (benefit) | $0.7 | $(0.3) |
| Effective tax rate including discrete items | 4.7% | 50.2% |

Income taxes - Our effective tax rate including discrete items for the three month periods ended November 30, 2016 and November 30, 2015 was 4.7% and 50.2%, respectively. The change in the effective tax rate, detailed in Note G, is primarily driven by the impact of the US valuation allowance and the deferred tax liability related to intangibles that have an indefinite reversal period and cannot be used to support the deferred tax assets.

### Results of Operations for the Six Months ended November 30, 2016 and November 30, 2015

For the six months ended November 30, 2016, we reported net income of $15.0 million, or $0.41 per diluted share, on net sales of $177.1 million, compared with a net loss of $1.1 million, or $0.03 per share, on net sales of $173.0 million during the same quarter of the prior year.

### Net Sales

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns.

Net sales for the six months ended November 30, 2016 and November 30, 2015:

| Net Sales by Product Category | Six months ended Nov 30, 2016 | Nov 30, 2015 | % Growth | Currency Impact (Pos) Neg | Constant Currency |
| --- | ---: | ---: | ---: | ---: | ---: |
| Peripheral Vascular | $104,304 | $98,161 | 6% |  |  |
| Vascular Access | 48,558 | 49,665 | (2)% |  |  |
| Oncology/Surgery | 22,844 | 23,805 | (4)% |  |  |
| Total Excluding Supply Agreement | 175,706 | 171,631 | 2% | 1% | 3% |
| Supply Agreement | 1,421 | 1,406 | 1% | —% | 1% |
| Total | $177,127 | $173,037 | 2% | 1% | 3% |
| Net Sales by Geography |  |  |  |  |  |
| United States | $142,535 | $139,022 | 3% | —% | 3% |
| International | 33,171 | 32,609 | 2% | 1% | 3% |
| Supply Agreement | 1,421 | 1,406 | 1% | —% | 1% |
| Total | $177,127 | $173,037 | 2% | 1% | 3% |

For the six months ended November 30, 2016, net sales increased $4.1 million to $177.1 million compared to the same period in the prior year. As shown in the table above, consolidated net sales increased by 2% and 3% on a constant currency basis.

From a product line perspective, Peripheral Vascular sales increased 6% primarily attributable to increased volume in our Angiographic product line which is offsetting softness in the remaining Peripheral Vascular business. Vascular Access sales decreased 2% due to growth in our Midlines and Bioflo dialysis product lines offsetting softness in the remaining Vascular Access. Oncology Surgery sales decreased 4% relating to the timing of capital product sales versus the prior year.

From a geographic perspective, U.S. sales increased 3% due primarily to increased volume in the Angiographic product line, BioFlo Midlines and NanoKnife product lines. International sales increased 3% on a constant-currency basis, primarily attributable to growth in the Angiographic offset by NanoKnife capital timing compared to the prior year.

### Gross Profit, Operating expenses, and Other income (expense)

|  | Six months ended Nov 30, 2016 | Nov 30, 2015 | % Change |
| --- | ---: | ---: | ---: |
| Gross profit | $90.0 | $89.3 | 1% |
| Gross profit % of sales | 50.8% | 51.6% |  |
| Research and development | $12.6 | $12.3 | 2% |
| % of sales | 7.1% | 7.1% |  |
| Selling and marketing | $39.0 | $42.6 | (8)% |
| % of sales | 21.8% | 24.6% |  |
| General and administrative | $16.0 | $16.0 | —% |
| % of sales | 8.9% | 9.2% |  |
| Medical device excise tax | $— | $2.0 | -100% |
| % of sales | —% | 1.1% |  |

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead. The $0.7 million increase compared to the six months ended November 30, 2015 is primarily attributable to sales volume and leverage in the plant offset by pricing pressures globally, foreign currency impacts and mix of products compared to prior year.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical, regulatory and medical affairs. R&D expenses increased $0.3 million for the six months ending November 30, 2016 due to increased headcount in regulatory and quality ($0.5 million) offset by lower project spend related to implementation of a new product development process ($0.3 million).

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities. S&M expenses decreased by $3.6 million for the six months ending November 30, 2016 due to open positions and commissions ($1.0 million), reduced travel costs ($1.1 million), depreciation expense ($0.3 million) and cost management on sales meetings and samples ($1.0 million).

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. G&A expenses remained consistent for the six months ended November 30, 2016, driven by lower depreciation ($0.4 million) offsetting increased legal fees and accounting fees ($0.3 million).

Medical device excise tax - Medical devices excise tax is assessed on our US product sales subject to exclusions and adjustments during the first two quarters of fiscal 2016. The expense decreased for the six months ending November 30, 2016 compared to the prior year due to the suspension of the medical device excise tax as of the end of December 2015.

|  | Six months ended Nov 30, 2016 | Nov 30, 2015 | $ Change |
| --- | ---: | ---: | ---: |
| Amortization of intangibles | $8.5 | $8.9 | $(0.4) |
| Change in fair value of contingent consideration | $(15.5) | $0.7 | $(16.2) |
| Acquisition, restructuring and other items, net | $10.3 | $6.1 | $4.2 |
| Other expense | $(1.8) | $(2.2) | $0.4 |

Amortization of intangibles - Amortization of intangibles decreased from the six months ending November 30, 2016 to November 30, 2015 primarily due to intangibles that became fully amortized.

Change in fair value of contingent consideration - Represents changes in the contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration. The decrease is due to a gain of $13.4 million that was taken on the AngioVac product as a result of decreases in future sales forecasts that eliminated any excess payments and a gain of $3.1 million on the TiLo product as the milestone will not be achieved. This was partially offset by normal amortization.

Acquisition, restructuring and other items, net - Expense for the six months ended November 30, 2016 consists primarily of $0.7 million in severance, $3.6 million in litigation expense and $2.0 million for the write-off of Embomedics due to termination of the agreement and $3.6 million related to the decision to discontinue our investment in the TiLo product, as described above. The six months ended November 30, 2015 included $0.4 million in accelerated depreciation, $2.6 million in litigation expense and other miscellaneous items.

Other expenses - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs. Expenses were consistent year over year in composition.

|  | Six months ended Nov 30, 2016 | Nov 30, 2015 |
| --- | ---: | ---: |
| Income tax expense (benefit) | $2.3 | $(0.3) |
| Effective tax rate including discrete items | 13.2% | 19.4% |

Income taxes - Our effective tax rate including discrete items for the six month periods ended November 30, 2016 and November 30, 2015 was 13.2% and 19.4%, respectively. The change in the effective tax rate, detailed in Note G, is primarily driven by the impact of the US valuation allowance and the deferred tax liability related to intangibles that have an indefinite reversal period and cannot be used to support the deferred tax assets.

### Liquidity and Capital Resources

Our cash and cash equivalents totaled $35.7 million as of November 30, 2016, compared with $32.3 million as of May 31, 2016. Marketable securities totaled $1.2 million and $1.7 million as of November 30, 2016 and May 31, 2016, respectively, and consist of an auction rate security. As of November 30, 2016, total debt was $116.5 million and the fair value of contingent consideration payments was $12.5 million.

The table below summarizes our cash flows for the six months ended November 30, 2016 and November 30, 2015 (in thousands of dollars):

| Cash provided by (used in): | Six Months Ended Nov 30, 2016 | Nov 30, 2015 |
| --- | ---: | ---: |
| Operating activities | $22,387 | $14,278 |
| Investing activities | (1,396) | (1,143) |
| Financing activities | (17,402) | (12,370) |
| Effect of exchange rate changes on cash and cash equivalents | (258) | (160) |
| Net change in cash and cash equivalents | $3,331 | $605 |

Cash provided by operating activities during the six months ended November 30, 2016 and November 30, 2015, was primarily the result of net income excluding non-cash items offset by changes in working capital. In the current year period, favorable working capital changes in accounts receivable were offset by unfavorable movements in inventories, payables and accrued expenses; however, working capital changes were $2.5 million more favorable than the prior year.

The net cash used in investing activities for the current year period consisted of $1.8 million in fixed asset additions offset by proceeds from one of our investments of $0.5 million. The prior year use of cash consisted primarily of $1.2 million of fixed asset additions.

The net cash provided by financing activities is the result of a $6.4 of proceeds from stock option and ESPP activity offset by a $9.9 million payment on earn-out liabilities, net $5.0 million in repayments on long-term debt after the proceeds from the new credit agreement and repayment of the old credit agreement, $1.2 million in deferred financing fees related to the new credit agreement and $7.9 million from the repurchase of common shares.

On November 7, 2016 the Company entered into a Credit Agreement that provides for a $100 million senior secured term loan facility and a $150 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans.

We believe that our current cash and investment balances, together with cash generated from operations and our remaining revolving credit facility capacity of $134.0 million as of November 30, 2016, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future, we may require additional external financing.

## Market risk

As filed, 1,586 characters.

We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.

We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. Approximately 7% of our year to date sales in fiscal 2017 were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other Income (Expenses).

On November 7, 2016, we entered into a Credit Agreement (the "Credit Agreement") which provides for a $100 million senior secured term loan facility ("Term Loan") and a $150 million senior secured revolving credit facility (the "Revolving Facility", and together with the Term Loan, the "Facilities"). Interest on both the Term Loan and Revolver is based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. In the event of default, the interest rate may be increased by 2.0%. Changes in the interest rate would not be material.

## Controls and procedures

As filed, 1,362 characters.

### Evaluation of disclosure controls and procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting for the fiscal quarter ended November 30, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 684 characters.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2016 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

Filed Jan 6, 2017.
Source: SEC EDGAR, the filing index for accession 0001275187-17-000005. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.
